Deals

*Boan Biotech Out-Licenses Japan Rights to Denosumab Biosimilar BA6101 in Upfront, Milestone, and Royalty Deal
BiosimilarsBoan Biotechnology

Boan Biotech Out-Licenses Japan Rights to Denosumab Biosimilar BA6101 in Upfront, Milestone, and Royalty Deal

Shandong Boan Biotechnology Co., Ltd. (HKG: 6955) announced that it has entered into a collaboration agreement with a partner for the Japan rights to its denosumab injection 60 mg (BA6101),…

Everest Medicines Signs Strategic Cooperation Agreement with Hi-Sen Pharmaceutical to Supply and Commercialize Six Products in China

Everest Medicines Signs Strategic Cooperation Agreement with Hi-Sen Pharmaceutical to Supply and Commercialize Six Products in China

Betta Pharmaceuticals Acquires Global Rights to SS202 Ultra‑Long‑Acting Monthly Growth Hormone from Gensciences – Deal Valued at Up to RMB 50 Million Plus Royalties

Betta Pharmaceuticals Acquires Global Rights to SS202 Ultra‑Long‑Acting Monthly Growth Hormone from Gensciences – Deal Valued at Up to RMB 50 Million Plus Royalties

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Finanical ReportsOTC / retail

Zuellig Pharma Expands Commercialization Deal for Karo Healthcare’s Lamisil in Asian Markets

CAR-TCell-therapy

Suzhou Porton Biologics Partners with Kunshi Biotech to Advance Third-Generation CAR-M Therapy

CRO / CMO / CDMOFinance

Shanghai Winpu Technology and Silver Mars Merge Under YinKe Holding to Accelerate Healthcare Innovation

AstraZenecaAZ

AstraZeneca to Acquire Fusion Pharmaceuticals in a Deal Valued at USD 2.4 Billion

Show More